Long-Term Survival of Older Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agent Therapy: A Large Population-Based Analysis

被引：0
|
作者：
Stahl, Maximilian
Hu, Xin
Wang, Rong
Ma, Xiaomei
Huntington, Scott
Podoltsev, Nikolai A.
Gore, Steven D.
Abel, Gregory A.
Davidoff, Amy J.
Zeidan, Amer M.
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
343
引用
收藏
页数：2
相关论文
共 50 条
  • [1] HYPOMETHYLATING AGENT THERAPY USE AND SURVIVAL IN OLDER PATIENTS WITH HIGHER RISK MYELODYSPLASTIC SYNDROMES IN USA: A LARGE POPULATION-BASED STUDY
    Zeidan, A.
    Hu, X.
    Long, J. B.
    Wang, R.
    Huntington, S. F.
    Podoltsev, N.
    Giri, S.
    Stahl, M.
    Gore, S.
    Ma, X.
    Davidoff, A. J.
    [J]. LEUKEMIA RESEARCH, 2017, 55 : S75 - S76
  • [2] Hypomethylating agent (HMA) therapy use and survival in older patients with higher risk myelodysplastic syndromes (HR-MDS) in the United States (USA): A large population-based study.
    Zeidan, Amer M.
    Hu, Xin
    Long, Jessica B.
    Wang, Rong
    Huntington, Scott F.
    Podoltsev, Nikolai Alexandrovich
    Giri, Smith
    Stahl, Maximilian
    Gore, Steven
    Ma, Xiaomei
    Davidoff, Amy J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [3] Does Provider Experience Treating Patients (pts) with Myelodysplastic Syndromes (MDS) Explain Duration of Hypomethylating Agent (HMA) Therapy and Overall Survival (OS)? A Large Population-Based Analysis
    Zeidan, Amer M.
    Hu, Xin
    Zhu, Weiwei
    Stahl, Maximilian
    Giri, Smith
    Huntington, Scott F.
    Wang, Rong
    Podoltsev, Nikolai A.
    Gore, Steven D.
    Ma, Xiaomei
    Davidoff, Amy J.
    [J]. BLOOD, 2018, 132
  • [4] HYPOMETHYLATING AGENT THERAPY USE AND SURVIVAL IN OLDER PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA IN USA: A LARGE POPULATION-BASED STUDY
    Zeidan, A.
    Hu, X.
    Long, J. B.
    Wang, R.
    Ma, X.
    Podoltsev, N.
    Huntington, S.
    Gore, S. D.
    Davidoff, A. J.
    [J]. LEUKEMIA RESEARCH, 2017, 55 : S20 - S21
  • [5] Hypomethylating Agent Therapy and Survival Among Older Patients with Chronic Myelomonocytic Leukemia in the United States: A Large Population-Based Study
    Zeidan, Amer M.
    Hu, Xin
    Long, Jessica B.
    Wang, Rong
    Huntington, Scott F.
    Podoltsev, Nikolai A.
    Gore, Steven
    Ma, Xiaomei
    Davidoff, Amy J.
    [J]. BLOOD, 2016, 128 (22)
  • [6] Hypomethylating Agent Therapy Use and Survival in Older Patients With Chronic Myelomonocytic Leukemia in the United States: A Large Population-Based Study
    Zeidan, Amer M.
    Hu, Xin
    Long, Jessica B.
    Wang, Rong
    Ma, Xiaomei
    Podoltsev, Nikolai A.
    Huntington, Scott F.
    Gore, Steven D.
    Davidoff, Amy J.
    [J]. CANCER, 2017, 123 (19) : 3754 - 3762
  • [7] Practical Recommendations for Hypomethylating Agent Therapy of Patients With Myelodysplastic Syndromes
    Steensma, David P.
    Stone, Richard M.
    [J]. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2010, 24 (02) : 389 - +
  • [8] Failure of Hypomethylating Agent-Based Therapy in Myelodysplastic Syndromes
    Kadia, Tapan M.
    Jabbour, Elias
    Kantarjian, Hagop
    [J]. SEMINARS IN ONCOLOGY, 2011, 38 (05) : 682 - 692
  • [9] Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: Retrospective analysis of survival after long-term follow-up
    Cabrero, Monica
    Jabbour, Elias
    Ravandi, Farhad
    Bohannan, Zach
    Pierce, Sherry
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    [J]. LEUKEMIA RESEARCH, 2015, 39 (05) : 520 - 524
  • [10] The long term risk of myelodysplastic syndromes among anemia patients: A population-based study
    Meytes, D.
    Chodick, G.
    Shalev, V.
    Porath, A.
    [J]. LEUKEMIA RESEARCH, 2012, 36 (03) : 327 - 330
12345